Cargando…
Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial
BACKGROUND: High miR-31-3p expression is associated with inferior outcomes in KRAS wild-type (WT) advanced colorectal cancer patients treated with anti-EGFR therapy. This study evaluated miR-31-3p expression in patients with operable colorectal liver metastases (LM) enrolled in the New EPOC study. M...
Autores principales: | Pugh, Siân, Thiébaut, Raphaële, Bridgewater, John, Grisoni, Marie-Lise, Moutasim, Karwan, Rousseau, Francis, Thomas, Gareth J., Griffiths, Gareth, Liebaert, François, Primrose, John, Laurent-Puig, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706840/ https://www.ncbi.nlm.nih.gov/pubmed/29212194 http://dx.doi.org/10.18632/oncotarget.21291 |
Ejemplares similares
-
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
por: Bridgewater, John A, et al.
Publicado: (2020) -
Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study
por: Pugh, Siân A, et al.
Publicado: (2016) -
Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification
por: Sreekumar, Rahul, et al.
Publicado: (2018) -
Agudización de la EPOC
Publicado: (2017) -
Exacerbación de la EPOC
por: Calle Rubio, Myriam, et al.
Publicado: (2010)